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Abstract
Introduction
There is a high degree of inter-individual variability among people in response to interven-
tion with omega-3 fatty acids (FA), which may partly explain conflicting results on the effec-
tiveness of omega-3 FA for the treatment and prevention of chronic inflammatory diseases.
In this study we sought to evaluate whether part of this inter-individual variability in response
is related to the regulation of key oxylipin metabolic genes in circulating peripheral blood
mononuclear cells (PBMCs).
Methods
Plasma FA and oxylipin profiles from 12 healthy individuals were compared to PBMC gene
expression profiles following six weeks of supplementation with fish oil, which delivered 1.9
g/d eicosapentaenoic acid (EPA) and 1.5 g/d docosahexaenoic acid (DHA). Fold changes
in gene expression were measured by a quantitative polymerase chain reaction (qPCR).
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Results
Healthy individuals supplemented with omega-3 FA had differential responses in prosta-
glandin-endoperoxide synthase 1 (PTGS1), prostaglandin-endoperoxide synthase 2
(PTGS2), arachidonate 12-lipoxygenase (ALOX12), and interleukin 8 (IL-8) gene expres-
sion in isolated PBMCs. In those individuals for whom plasma arachidonic acid (ARA) in the
phosphatidylethanolamine (PE) lipid class decreased in response to omega-3 intervention,
there was a corresponding decrease in gene expression for PTGS1 and ALOX12. Several
oxylipin product/FA precursor ratios (e.g. prostaglandin E2 (PGE2)/ARA for PTGS1 and 12-
hydroxyeicosatetraenoic acid (12-HETE)/ARA for ALOX12) were also associated with fold
change in gene expression, suggesting an association between enzyme activity and gene
expression. The fold-change in PTGS1 gene expression was highly positively correlated
with ALOX12 gene expression but not with PTGS2, whereas IL-8 and PTGS2 were posi-
tively correlated.
Conclusions
The regulation of important oxylipin metabolic genes in PBMCs varied with the extent of
change in ARA concentrations in the case of PTGS1 and ALOX12 regulation. PBMC gene
expression changes in response to omega-3 supplementation varied among healthy indi-
viduals, and were associated with changes in plasma FA and oxylipin composition to differ-
ent degrees in different individuals.
Trial Registration
clinicaltrials.gov NCT01838239
Introduction
Omega-3 fatty acids (FA) work as therapeutic agents by a wide range of biological mechanisms
leading to anti-inflammatory and immune modulating effects. Most individuals consuming a
Western diet are likely to be effectively deficient in long-chain omega-3 FA since the Western
diet is heavily skewed toward omega-6 FA. Globally, humans currently consume an omega-6:
omega-3 ratio closer to 15:1, which is dramatically shifted from the historical ratio of 2:1[1].
Omega-3 and omega-6 FA are essential because humans lack the specific desaturase enzyme
required for their production. The polyunsatured fatty acids (PUFA) can be converted into
oxylipins by interaction with reactive oxygen and three main classes of enzymes including
cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP) [2]. The COX path-
way generates several pro-coagulant and proliferative metabolites from arachidonic acid
(ARA) including prostaglandins (e.g. PGE2) and thromboxanes (e.g. TXB2). The EPA COX
products PGD3 and PGE3 are less proliferative than their ARA counterparts, whereas Resolvin
E1 is pro-resolving (i.e. leads to cessation of inflammation). Pro-inflammatory products are
produced from ARA via the 5-LOX pathway (e.g. 5-hydroxyeicosatetraenoic acid (5-HETE)).
This pathway also generates hydroxypentaenoic acids (HEPEs) from EPA. Some other pro-
inflammatory products come from the 12- and 15-LOX pathways such as 9-HETE, 11-HETE,
12-HETE, 15-HETE, and metabolites from linoleic acid (LA). In fact over 90 bioactive oxyli-
pins are produced from omega-3 and omega-6 FA. These oxylipins form a complex mixture
White Blood Cell Gene Expression and Lipidomic Profiles after Omega-3
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that induces both pro- and anti- inflammatory effects depending on the site of action, the cell
from which they are produced, and the stage of inflammation. In general the omega-3 oxylipins
are antagonistic to the actions of the omega-6 oxylipins [3] and are thus considered to be anti-
inflammatory and pro-resolving.
The latest research on omega-3 FA and their beneficial effects in diseases such as cardiovas-
cular disease have been inconsistent, with large clinical trials reporting benefit, no benefit, and
even detrimental effects in some cases. In fact, recent meta-analyses have found the literature
inconsistent enough to call into question the recommendation to use omega-3 FA for the treat-
ment and prevention of inflammatory diseases such as heart disease [4]. Recently, we showed
that this observed inconsistency in the literature on the effects of omega-3 FA may be due in
part to the high degree of inter-individual variability among people in response to intervention
with omega-3 FA[5]. We found that while certain aspects of response to intervention were uni-
versal across all of the subjects, the magnitude and sometimes both the magnitude and direc-
tion of response in both FA and oxylipin profiles were highly variable.
The aim of this pilot study was to determine whether the observed inter-individual variabil-
ity in response to omega-3 FA intervention may be due to variability in the regulation of gene
transcription of key genes involved in the production of inflammatory lipid mediators. The pri-
mary outcomes were correlations among the fold changes in gene expression in circulating
immune cells and percentage changes in plasma FA and oxylipins.
Materials and Methods
Clinical protocol
All of the clinical study parameters are described in Nording et al. [5]. The study was an open
label and single arm intervention study. Recruitment took place on the University of California
Davis campus and included posting of flyers as well as announcements at seminars. Eligibility
criteria included age 18–65, not being pregnant or nursing, not having any existing conditions
or diseases, BMI 18–30, not having anemia and/or other conditions affecting ability to donate
blood safely, not recently recovering from illnesses, injuries, or infections, able and willing to
take 6 g of fish oil every day for 6 weeks, able to stop or avoid taking NSAID and other anti-
inflammatory medications (e.g. allergy medications) and able and willing to avoid consuming
seafood for 6 weeks.
Subjects came to the study site (the Ragle Human Nutrition Center on the University of Cal-
ifornia Davis campus) three times. At the first visit subjects were screened and filled out ques-
tionnaires about their health and medications, and height and weight was measured to assess
their eligibility. If subjects met eligibility criteria they were consented to participate in the
study. At the second (i.e. baseline or pre intervention) and third (i.e. post intervention) visits
subjects came to the study center in the morning after an overnight fast. Blood samples were
collected by venipuncture using BD Vacutainer lavender-top EDTA tubes, and height and
weight were measured. Within 15 minutes of collection whole blood was centrifuged in a table-
top centrifuge (10 minutes, 4°C, 13,000 rpm) and the plasma was immediately aliquoted and
frozen at -70°C until they were analyzed. At the baseline or pre intervention visit, subjects
received their intervention, which consisted of 6 individual bottles each containing a week’s
worth of fish oil capsules. Subjects received instructions to take 6 1-gram capsules each day and
to continue consuming their regular diets but to abstain from consuming any seafood or taking
any other fish oil supplements. The fish oil capsules totaled 1.9 g/d EPA and 1.5 g/d DHA each
day, and were from Ocean Nutrition (lot 18394). Each capsule was composed of 35% EPA,
26% DHA, 11% 20:1n9, 6% 22:5n3, 6% 22:1n11, 2% 18:1n9, 2% 20:4n6, 2% 20:4n3, with the
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remainder consisting of other minor FA each at1% concentration. Subjects were contacted
throughout the study by e-mail and/or phone by study personnel to encourage compliance.
After 6 weeks at the post-intervention visit subjects returned to the study site and another
fasting blood draw was taken, and weight and height was measured. Subjects reported their die-
tary intake with 3-day diet records at the start and end of the study. Subjects were compensated
with gift cards and were given their baseline lipid results. The consort diagram (Fig 1) shows
that 23 subjects were screened, 10 were excluded (6 were either taking medications or were not
Fig 1. Consort Diagram.
doi:10.1371/journal.pone.0144996.g001
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willing to abstain from taking medications and 4 declined enrollment), and the remaining 13
were enrolled. One subject dropped from the study after the first day of the intervention due to
gastrointestinal discomfort (diarrhea). The remaining 12 subjects all completed the study and
were included in analysis, and consisted of 8 female and 4 male subjects. No adverse events
were reported however 2 of the female subjects reported that their menstrual cycles were longer
than normal during the intervention. The 12 subjects who completed the study had the follow-
ing mean (± SD) characteristics: age, 32 ± 8 y; weight, 67 ± 17 kg; body mass index (BMI),
23 ± 3 kg/m2 (median: 22, range: 18–28) (individual characteristics shown in S1 Table).
The date range for participant recruitment and follow-up was May 03, 2007 through Janu-
ary 18, 2010. This trial was registered at clinicaltrials.gov as NCT01838239. This study was reg-
istered after enrollment of participants started due to an unintentional administrative delay.
The authors confirm that all ongoing and related trials for this intervention are registered.
Sample size calculations were not performed due to the exploratory nature of this study.
Ethics Statement
This study followed the principles expressed in the Declaration of Helsinki. The experimental
protocol was approved by the Institutional Review Board of the University of California Davis
on May 03. 2007, and written informed consent was obtained from all of the subjects.
PBMC isolation and RNA extraction
10 mL of whole anticoagulated blood was centrifuged at 5000g at 4°C for 15 min (Beckman
Coulter Allegra 6R Centrifuge). Following centrifugation, the plasma layer was removed and
the PBMC layer was carefully isolated, transferred to a tube with 2 mL of sterile PBS, and care-
fully mixed. The PBMC+PBS mixture was gently layered onto Ficoll-Paque (Sigma-Aldrich)
and centrifuged at 450g for 10 min. After centrifugation, the supernatant was removed and the
cells were re-suspended and transferred into 15 mL tubes with 5 mL of PBS and mixed gently
prior to a second centrifugation at 450g for 10 min. Finally, the cells were re-suspended in 1
mL of PBS and centrifuged at 1000g in a micro-centrifuge (Eppendorf Micro Centrifuge
5417R) for 1 min at 4°C. After centrifugation the cells were re-suspended in 400 μL of RNA
Later (Ambion), stored overnight at 4°C and then at -80°C until RNA extraction. Total RNA
was extracted from 2 x 107 cells using TRIzol Reagent (Life Technologies) in combination with
a PureLink RNAMini Kit (Life Technologies). The concentration and integrity of the RNA
samples were determined using an Experion Automated Electrophoresis System (BioRad), and
only RNA with a RNA quality indicator (RQI) value greater than 9.2 was used in the cDNA
synthesis reaction.
TaqMan Real-Time RT-PCR
First-strand cDNA was synthesized from 168 ng of total RNA by using a High-Capacity cDNA
Reverse Transcription kit (Applied Biosystems) under conditions recommended by the manu-
facturer. The expression levels of 4 endogenous control genes (Actin, GAPDH, HPRT1, and
GUSB) and 92 target genes were quantified using custom pre-designed TaqMan probes and
primers in a 96 well-plate format (Applied Biosystems). Primer and probe sequences and qual-
ity controls, including gene amplification specificities, were provided by the manufacturer.
Briefly, the cDNA amplification was performed on 50-fold diluted cDNA samples using Taq-
Man Fast Advanced Master Mix (Applied Biosystems), and the following cycling conditions
were run on a Prism 7500 Fast real-time PCR thermocycler (Applied Biosystems): 50°C/ 2 min;
95°C/ 20 sec; and 40 cycles of 95°C/ 3sec; 60°C/ 30 sec.
White Blood Cell Gene Expression and Lipidomic Profiles after Omega-3
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The Pfaffl method [6] was used to calculate the expression levels of the target genes in the
post-treatment samples relative to the corresponding baseline control samples within each sub-
ject and normalized against HPRT1 and GUSB. Individual amplification efficiencies were ana-
lyzed for each reaction by LinRegPCR software (HFRC version 2014.2, [7]) and ΔCt values
were corrected by their corresponding individual efficiencies.
Fatty acid analysis
Fatty acid analysis was performed by Lipomics Technologies Inc. (West Sacramento, CA)
according to the method described by Watkins et al. [8]. Coefficients of variation for this
method are described in Zivkovic et al. [9]. Briefly, by using a modified Folch extraction [10],
the lipids from plasma were extracted and then separated by preparative high-pressure liquid
chromatography into seven lipid classes: cholesterol esters (CE), diglycerides (DG), free fatty
acids (FFA), lyso phosphatidylcholine (LY), phosphatidylcholine (PC), phosphatidylethanol-
amine (PE), and triglycerides (TG). Internal standards were used and calibration curves were
calculated in order to quantify the fatty acids. FA methyl esters, from all lipid classes, produced
by trans-esterification were extracted and analyzed by gas chromatography. All of the FA were
quantified (nmol FA/g plasma) in each lipid class and summed in order to obtain total lipid
class quantities. Enzyme activity was measured from product/precursor ratios as described in
Warensjö et al. [11]. Warensjö et al. showed that 16:1n7/16:0 and 18:1n9/18:0 are highly corre-
lated with the activity of the stearoyl-CoA-desaturase (SCD) enzyme. In this study, the follow-
ing product/precursor ratios were used as indicators of the activities of PTGS1 and PTGS2:
PGE2/20:4n6, PGD2/20:4n6, PGF2α/20:4n6, and TXB2/20:4n6; ALOX 12: 12-HETE/20:4n6 and
12-HEPE/20:5n3; and CYP4A11: 20-HETE/20:4n6.
Oxylipin profiling
Oxylipins were analyzed as described in Yang et al. [12]. Briefly, samples were extracted by
solid phase extraction (SPE) and separated by liquid chromatography, followed by QTrap tan-
dem mass spectrometry. The instrument was operated in negative multiple reaction monitor-
ing (MRM) mode. Quality control samples were analyzed at a minimum frequency of 10
samples. Analyst software 1.4.2 was used to quantify the peaks according to the standard
curves. Oxylipin data were quantified and are presented as mol/L of plasma. Six batches of the
standard mixtures and three further dilutions were used to determine the Limit of Quantifica-
tion (LOQ) and linearity range. The calibration curves were calculated by least-squares linear
regression using an 1/x weighting factor. The standard concentrations were back-calculated
from the constructed calibrations curves for each analyte. Any oxylipins that were below LOQ
were excluded from analysis.
Statistical analysis
The following genes were excluded from the qPCR data analysis because they met one or more
of the following exclusion criteria 1) showed undetectable or unreliable expression levels
(Ct>35), 2) primers could potentially amplify genomic DNA, 3) amplification efficiencies were
outside of the acceptable range (1.85–2.00): IL1B, IL2, TNFAIP3, TLR1, VCAM1, TLR8,
CYP2J2,MYD88, TNFRSF11A, PTGES, EPHX3, EPHX4, TLR3, TLR4, NFKBIA, RELA,MYC,
IRAK1, LTBR, ICAM1, IL1R1, IL12A, IL10, TNF, IL6, CSF1, NFKB2, IKBKG, IRAK2,MAP3K7,
MAP3K14, TBK1, BCL3, FASLG, NFKBIB, BTRC, TRAF5, TRAF2, CD83, TRAF4, TRAF1,
ALOX5, ENPP2, CREB1, CREBBP, CCL2, NFKBIE, STAT1, TRAF3, TNFSF11, PTAFR,
TNFRSF10A, TLR6, PLA2G7, TNFS15, TNFRSF10B, LTA4H, TBXAS1, TLR9, PTGDS,
MAP3K1, IKBKB, IRAK1BP1, ZNF675, BCL2, TLR7, NFKB1, IL2RA, BCL10, REL, EPHX1,
White Blood Cell Gene Expression and Lipidomic Profiles after Omega-3
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CHUK, TNFRSF1A, EPHX2, TLR2, CD40, 18S, PTAFR, TLR6, TNFSF15, CD14, CYP4A11,
CRP, CSF3, NOS2, CYP2C19, SELE, IL1A, CYP4F2, IL12B, CARD14, PTGIS, and CSF3.
Product/precursor ratios were used as indicators of enzyme activity for PTGS1, PTGS2,
ALOX12, and CYP4A11. For PTGS1 and PTGS2 the following ratios were used: PGE2/20:4n6,
PGD2/20:4n6, PGF2α/20:4n6, and TXB2/20:4n6. For ALOX12 the following ratios were used:
12-HETE/20:4n6, and 12-HEPE/20:5n3. For CYP4A11 the ratio 20-HETE/20:4n6 was used.
For each of these sets of ratios the FA from each of the 7 lipid classes were examined.
Percentage change for each variable was calculated as ðPostPreÞ
Pre
 100. The percentage change
(% change) in the following variables was analyzed for correlations with fold-change in gene
expression using Pearson product-moment correlation analysis: ARA, EPA, DHA, PGE2,
PGD2, PGF2α, TXB2, 12-HETE, 12-HEPE, 20-HETE, and the appropriate product/precursor
ratios for each gene as described above. Pearson product-moment correlation analysis was also
used to examine the correlations between BMI and the fold changes in gene expression and %
changes in oxylipins, FA, and oxylipin/FA ratios. Significance was set at α 0.05. The Fisher
transformation was used to evaluate statistical significance and to obtain 95% confidence inter-
vals. No adjustments were made for multiple testing due to the exploratory nature of the analy-
ses. The data were analyzed using JMP12 Pro software (SAS Institute, Inc., Cary, NC).
Results
Five genes met all quality control criteria and were included in the subsequent analysis evaluat-
ing their relationships with plasma FA and oxylipin profiles: PTGS1, PTGS2, ALOX12, IL-8,
and CYP4A11. The fold change results (mean ± SD) for the 5 included genes were as follows:
PTGS1–0.14 ± 2.29; PTGS2–0.18 ± 3.65; ALOX12–0.06 ± 2.77; IL-8–2.02 ± 5.58; CYP4A11
1.10 ± 1.90. A scatterplot matrix of correlations among the 5 genes as well as BMI, % change in
PE ARA, EPA, and EPA/ARA ratio is depicted in Fig 2. Across all 5 genes there was a range of
responses from a negative fold change in gene expression to a positive fold change (minimum,
maximum): PTGS1–3.7, +2.8; PTGS2–5.9, +8.3; ALOX12–3.6, +5.5; IL-8–8.6, +10; CYP4A11–
1.8, +3.4. Contrary to most research showing that PTGS1 (COX1) and PTGS2 (COX2) are
commonly co-regulated we found no correlation between the fold-change in gene expression
of these two iso-enzymes in PBMCs following omega-3 supplementation (p = 0.7249; r =
-0.1137). On the other hand, we found a significant positive correlation between IL-8 and
PTGS2 (p = 0.0041, r = 0.7598, confidence interval (CI): 0.3297, 0.9287) as well as a highly sig-
nificant positive correlation between PTGS1 and ALOX12 fold change in gene expression (p =
<0.0001; r = 0.8993, CI: 0.6725, 0.9717).
There was only one statistically significant correlation between fold change in PTGS1 and %
change in ARA, EPA, or DHA, which was the % change in PE ARA (p = 0.0044, r = 0.7564, CI:
0.3224, 0.9276) (Fig 2). Neither EPA nor DHA from any lipid class were correlated with
PTGS1. Statistically significant correlations between fold change in PTGS1 and % change in
oxylipin/FA ratios are shown in Table 1. All of these % changes in oxylipin/FA ratios were pos-
itively correlated with fold change in PTGS1. Percentage changes in the PTGS1 products TXB2
(p = 0.0100, r = 0.7078, CI: 0.2256, 0.9115) and PGD2 (p = 0.0422, r = 0.5929, CI: 0.0288,
0.8706) were also positively correlated with fold change in PTGS1.
Just as with PTGS1, the only significant correlation between ALOX12 and ARA, EPA, or
DHA was % change in PE ARA (Fig 2). Table 2 shows the significant correlations between fold
change in ALOX12 and % changes in oxylipin/FA ratios, all of which were positive correlations
just as with PTGS1. In this case, the ratios of both the omega-6 ARA and its corresponding
ALOX12 oxylipin product 12-HETE, and the ratios of omega-3 EPA and its corresponding
product 12-HEPE were significantly correlated with ALOX12. However, only the % change in
White Blood Cell Gene Expression and Lipidomic Profiles after Omega-3
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12-HETE (p = 0.0052, r = 0.7475, CI: 0.3040, 0.9247) but not 12-HEPE (p = 0.2001, r = 0.3979)
was significantly correlated with ALOX12.
There were no statistically significant correlations between fold change in CYP4A11 and %
change in any of the FA, its product 20-HETE, or any of the 20-HETE/ARA ratios (data not
shown). There were also no statistically significant correlations between fold change in PTGS2
and % change in any of the FA, oxylipins, or oxylipin/FA ratios (data not shown). Likewise,
there were no statistically significant correlations between IL-8 and any of the % changes in
EPA, DHA, or ARA (data not shown).
BMI was positively correlated with both PTGS1 (p = 0.0407, r = 0.5964, CI: 0.0342, 0.8719)
and ALOX12 (p = 0.0071, r = 0.7297, CI: 0.2680, 0.9188) fold change but not with any of the %
changes in product/precursor ratios or with any of the % changes in EPA, DHA, or ARA or
their oxylipin metabolites. However, there was a non-statistically significant negative correla-
tion between % change in PE EPA and BMI (p = 0.0849, r = -0.5422, CI: -0.8618, -0.0855) (Fig
2), and % change in FFA EPA and BMI (p = 0.0502, r = -0.5755, CI: -0.8640, -0.0024). BMI was
not correlated with % change in PE ARA (p = 0.4004, r = 0.2676) however it was negatively
Fig 2. Scatterplot matrix of correlations among bodymass index (BMI), fold changes in gene expression of PTGS1, PTGS2, ALOX12,CYP4A11,
and IL-8, and percentage changes in phosphatidylethanolamine (PE) arachidonic acid (ARA, 20:4n6), PE eicosapentaenoic acid (EPA, 20:5n3),
and PE EPA/ARA ratio. Correlation analysis was conducted using Pearson product-moment correlation analysis. Statistically significant positive
correlations are shown highlighted with a blue background, and negative correlations are shown highlighted with a grey background.
doi:10.1371/journal.pone.0144996.g002
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Table 1. Correlations between percentage change in oxylipin product/fatty acid precursor ratios and
fold change in PTGS1 gene expression in response to 6 weeks of supplementation with omega-3 fatty
acids as fish oil.
% Change in Ratio* P-value r Confidence Interval^
PGE2/FFA 20:4n6 0.0023 0.7887 0.3924–0.9380
PGD2/FFA 20:4n6 0.0023 0.7892 0.3935–0.9382
PGD2/LY 20:4n6 0.0250 0.6398 0.1042–0.8878
PGD2/PC 20:4n6 0.0354 0.6095 0.0547–0.8767
PGD2/DG 20:4n6 0.0348 0.6109 0.0570–0.8773
PGD2/TG 20:4n6 0.0462 0.5839 0.0151–0.8672
TXB2/FFA 20:4n6 0.0102 0.7063 0.2226–0.9109
TXB2/PC 20:4n6 0.0173 0.6691 0.1545–0.8981
TXB2/TG 20:4n6 0.0201 0.6576 0.1344–0.8941
TXB2/PE 20:4n6 0.0282 0.6296 0.0872–0.8841
TXB2/LY 20:4n6 0.0320 0.6186 0.0693–0.8801
TXB2/DG 20:4n6 0.0361 0.6077 0.0518–0.8760
TXB2/CE 20:4n6 0.0437 0.5894 0.0234–0.8693
*PGE2: prostaglandin E2, PGD2: prostaglandin D2, TXB2: thromboxane B2, FFA: free fatty acid, LY:
lysophosphatidylcholine, PC: phosphatidylcholine, DG: diglyceride, TG: triglyceride, PE:
phosphatidylethanolamine, CE: cholesterol ester
^ 95% Confidence interval for the correlation calculated using the Fisher transformation.
doi:10.1371/journal.pone.0144996.t001
Table 2. Correlations between percentage change in oxylipin product/fatty acid precursor ratios and
fold change in ALOX12 gene expression in response to 6 weeks of supplementation with omega-3
fatty acids as fish oil.
% Change in Ratio* P-value r Confidence Interval^
12-HETE/TG 20:4n6 0.0025 0.7850 0.3842–0.9369
12-HETE/CE 20:4n6 0.0042 0.7591 0.3281–0.9285
12-HETE/FFA 20:4n6 0.0083 0.7200 0.2489–0.9156
12-HETE/PC 20:4n6 0.0103 0.7060 0.2220–0.9108
12-HETE/LY 20:4n6 0.0194 0.6606 0.1397–0.8951
12-HETE/PE 20:4n6 0.0226 0.6484 0.1186–0.8908
12-HETE/DG 20:4n6 0.0267 0.6344 0.0952–0.8858
12-HEPE/CE 20:5n3 0.0036 0.7673 0.3456–0.9312
12-HEPE/TG 20:5n3 0.0102 0.7067 0.2235–0.9111
12-HEPE/LY 20:5n3 0.0286 0.6285 0.0855–0.8837
12-HEPE/PC 20:5n3 0.0304 0.6232 0.0767–0.8817
12-HEPE/PE 20:5n3 0.0377 0.6035 0.0452–0.8745
*12-HETE: 12-hydroxyeicosatetraenoic acid, 12-HEPE: 12-hydroxyeicosapentaenoic acid, FFA: free fatty
acid, LY: lysophosphatidylcholine, PC: phosphatidylcholine, DG: diglyceride, TG: triglyceride, PE:
phosphatidylethanolamine
^ 95% Confidence interval for the correlation calculated using the Fischer transformation., CE: cholesterol
ester
doi:10.1371/journal.pone.0144996.t002
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correlated with % change in the EPA/ARA ratio in the PE lipid class (p = 0.0248, r = -0.6406,
CI: -0.8880, -0.1055) (Fig 2) but not any of the other lipid classes.
Discussion
Our previously published paper describes in detail the effects of omega-3 supplementation on
plasma FA and oxylipin profiles [5]. Briefly, concentrations of EPA and DHA significantly
increased across lipid classes post supplementation as expected, however the magnitude of
response was highly variable. For example, change in PC EPA ranged from a 104% increase to
a 3,528% increase, and change in PE DHA ranged from a 4% decrease to a 187% increase. The
responses in neither the FA precursors (EPA, DHA, and ARA) nor their oxylipin products
were associated with age, gender, body weight, or BMI. It is possible however, that we may
have seen a dose-response for EPA with a larger sample size, given that there was some evi-
dence of a negative correlation between PE and FFA EPA and BMI in this study. Baseline mol
% of ARA in PE was negatively correlated with the % change in PE DHA, suggesting that in
individuals with high constitutive levels of PE ARA there is less incorporation of DHA into this
lipid class. Although concentrations of ARA decreased in most subjects, the differences in ARA
concentrations across lipid classes pre to post supplementation did not reach statistical signifi-
cance when the Bonferroni correction was applied. Several intermediates in the desaturation
and elongation pathway of ARA, including 18:3n6 and 20:3n6, decreased in response to the
omega-3 supplement, suggesting that the conversion of 18:2n6 to ARA was reduced, however,
the levels of ARA were preserved to a greater extent in some individuals than others.
In this study we found that healthy individuals supplemented with omega-3 FA had differ-
ential responses in PTGS1, PTGS2, ALOX12, IL-8, and CYP4A11 gene expression in isolated
PBMCs. For both PTGS1 and ALOX12, % change in PE ARA was positively correlated with a
change in gene expression in response to omega-3 supplementation. In those individuals for
whom plasma ARA in the PE lipid class decreased in response to omega-3 intervention, there
was a corresponding decrease in gene expression for PTGS1 and ALOX12 in PBMCs. On the
other hand, changes in EPA and DHA were not correlated with either PTGS1 or ALOX12 gene
expression changes. These findings suggest that the concentration of ARA, which is modified
by omega-3 supplementation, rather than the omega-3 EPA and DHA directly, may be
involved in regulating the expression of the PTGS1 and ALOX12 enzymes.
There were also positive correlations between fold change in PTGS1 and ALOX12 and %
change in their respective oxylipin/FA ratios, for instance PGE2/FFA ARA and 12-HETE/TG
ARA respectively. For ALOX12 the ratios of 12-HEPE to its FA precursor EPA across several
lipid classes were also positively correlated with fold change in gene expression. These results
suggest that the activities of the enzymes decreased concomitantly in those individuals for
whom gene expression decreased in response to supplementation. Together, these results sug-
gest that those individuals who have constitutively high levels of ARA in the PE lipid class
maintain their levels of PTGS1 and ALOX12 gene expression and activity in circulating mono-
cytes and may not see some of the expected anti-inflammatory benefits of omega-3 supplemen-
tation. On the other hand, in individuals whose levels of PE ARA decrease there may also be a
decrease in the gene expression and activity of PTGS1 and ALOX12.
We found positive correlations between BMI and fold change in the expression of PTGS1
and ALOX12 but not between BMI and % changes in ARA, EPA, or DHA across lipid classes,
or any of their oxylipin metabolites, or product/precursor ratios. Importantly, % change in PE
ARA was not correlated with BMI. This suggests that the changes in PE ARA were not likely a
simple dose-response to the omega-3 intervention. However, % change in the ratio EPA/ARA
in the PE lipid class was significantly negatively correlated with BMI although this ratio was
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not associated with the fold changes in any of the 5 genes. Also, there was a non-statistically
significant correlation between FFA EPA and PE EPA, and BMI. The correlations among
PTGS1 and ALOX12 fold change and the FA, oxylipins, and FA/oxylipin ratios were on the
whole stronger than the correlations with BMI, however, BMI appears to play a role in the
PBMC gene expression changes in these two enzymes in response to omega-3 intervention. In
previous studies, a dose-dependent effect was observed for phospholipid EPA/ARA ratios at
similar dosages of omega-3 in IgA nephropathy patients (significant negative correlation
between phosholipid EPA/ARA and dose of omega-3 fatty acids in g/kg body weight) [13].
However, in our study, neither the % changes in EPA nor the % change in the EPA/ARA ratio
were associated with fold change in the gene expression of PTGS1 and ALOX12. As mentioned
earlier, it is possible that our sample size was too small to detect a direct dose-response relation-
ship between fold change in the oxylipin metabolic genes and % change in EPA or EPA/ARA.
These observations merit further study in larger cohorts.
PTGS1 continues to be described as the constitutive isoform of the COX enzyme whereas
PTGS2 is considered the inducible form [14]. However, as early as 2000, Maldve et al. [15]
demonstrated that both isoforms were inducible by ARA and its PG metabolites in murine ker-
atinocytes. On the other hand, Vichai et al [16] showed positive feedback regulation of PTGS2
mRNA expression and protein activity but not PTGS1 by prostaglandin metabolites (PGE2 in
particular) in mouse lung fibroblasts. Thus, it appears that there is tissue-dependent variability
in the inducibility of the two COX isoforms.
The fold-change in PTGS1 gene expression was highly correlated with ALOX12 gene expres-
sion but not with PTGS2 gene expression. On the other hand, IL-8 and PTGS2 were positively
correlated. The co-correlation observed between ALOX12/PTGS1 and IL-8/PTGS2 could be
explained by the fact that these genes share some common transcription factors. All 4 of these
genes have AP-1 and c-Jun in common; however, PTGS1 and ALOX12 also have Sp1 in com-
mon whereas PTGS2 and IL-8 also have NF-kappa β and C/EBPα in common. It is possible
that the observed associations between PTGS1 and ALOX12 and between PTGS2 and IL-8 are
mediated through the induction of these transcription factors by changes in the FA composi-
tion of plasma.
The regulation of gene expression after omega-3 supplementation has been reviewed previ-
ously [17]. Omega-3 fatty acids influence the gene expression of a variety of important tran-
scription factors involved in regulating lipid metabolism, especially peroxisome proliferator-
activated receptor, sterol regulatory binding element protein, and nuclear factor kappa b. Spe-
cific downstream genes that have been shown to be down-regulated by omega-3 fatty acids
include IL-8 and PTGS2 [17]. A recent study investigating the effects of high dose EPA + DHA
supplementation on PBMC gene expression profiles in elderly individuals found down-regula-
tion of several oxylipin metabolism genes including leukotriene A4 (LTA4) hydrolase, which
converts LTA4 to leukotriene B4 (LTB4), and ALOX5 [18]. In the current study, we did not
find changes in the same genes however this may be due to the fact that our study population
was healthy young (age 18–55) individuals, whereas in the previously published study the sub-
jects were elderly (age 66–80). The current study may also have been underpowered to detect
these and other gene expression changes.
This study had several shortcomings. One of the challenges of testing multiple genes at once
on the same plate is that each gene has different amplification characteristics. Despite the man-
ufacturer’s attempts to standardize the plate across all of these genes on a custom plate, we still
found variability in the PCR performance. We applied stringent quality control steps into our
data analysis pipeline, which resulted in the exclusion of a large proportion of the 92 genes ana-
lyzed, in order to be able to analyze only those data that were most reliable. For those few genes
that remained, we feel that the data are robust, given the stringent quality control screening
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steps. Another shortcoming of this study is that our results are not average results from techni-
cal duplicate (or triplicate) analyses. Finally, this study was a pilot study performed in a cohort
of 12 healthy subjects. Therefore, it is possible that some of the correlations observed in these
analyses are due to spurious correlations resulting from small sample size, and conversely, it is
possible that some relationships were not detected due to the small sample size, and the results
should be interpreted with this in mind. Larger studies need to be performed to confirm these
findings and further explore the nature of the metabolic phenotype differences among those
individuals who appear to be responders compared to those who appear to be less responsive
to omega-3 supplementation.
Conclusions
The aim of this study was to determine whether the observed inter-individual variability in
lipid response to omega-3 FA intervention may be due to an underlying variability in the reg-
ulation of gene transcription of key genes involved in the production of inflammatory lipid
mediators. The results from this pilot study showed that the regulation of important oxylipin
metabolic genes (e.g. PTGS1, ALOX12) in PBMCs in response to omega-3 supplementation
were associated with the extent of change in ARA concentrations, particularly in the PE lipid
class. Plasma concentration of PE ARA may be a biomarker of differential phenotypes in
omega-3 response. Individuals with larger decreases in PE ARA after supplementation with
6 g/d fish oil had a larger decrease in the expression of PTGS1 and ALOX12. These results
suggest that the individual variability in response to omega-3 intervention in PBMC gene
expression may be dependent on the indirect effects of the omega-3 FA on ARA concentra-
tions rather than the extent of change to omega-3 concentrations themselves. Our results
provide preliminary in vivo evidence that plasma oxylipins may be products of PBMC
metabolism and that plasma FA and oxylipins are associated with PBMC gene expression in
response to omega-3 intervention. The results of this pilot study indicate that the gene
expression of key lipid metabolic genes in PBMCs varies with changes in plasma FA and oxy-
lipin composition in response to omega-3 supplementation to different degrees in different
individuals.
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